TY  - JOUR
AU  - Jost, Stefanie T.
AU  - Ray Chaudhuri, K.
AU  - Ashkan, Keyoumars
AU  - Loehrer, Philipp A.
AU  - Silverdale, Monty
AU  - Rizos, Alexandra
AU  - Evans, Julian
AU  - Petry-Schmelzer, Jan Niklas
AU  - Barbe, Michael T.
AU  - Sauerbier, Anna
AU  - Fink, Gereon R.
AU  - Visser-Vandewalle, Veerle
AU  - Antonini, Angelo
AU  - Martinez-Martin, Pablo
AU  - Timmermann, Lars
AU  - Dafsari, Haidar S.
TI  - Subthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study
JO  - Journal of Parkinson's Disease
VL  - 11
IS  - 1
SN  - 1877-718X
CY  - Amsterdam
PB  - IOS Press
M1  - FZJ-2021-03965
SP  - 323 - 335
PY  - 2021
AB  - Background:Sleep disturbances and neuropsychiatric symptoms are some of the most common nonmotor symptoms in Parkinson’s disease (PD). The effect of subthalamic stimulation (STN-DBS) on these symptoms beyond a short-term follow-up is unclear.Objective:To examine 36-month effects of bilateral STN-DBS on quality of sleep, depression, anxiety, and quality of life (QoL) compared to standard-of-care medical therapy (MED) in PD.Methods:In this prospective, controlled, observational, propensity score matched, international multicenter study, we assessed sleep disturbances using the PDSleep Scale-1 (PDSS), QoL employing the PDQuestionnaire-8 (PDQ-8), motor disorder with the Scales for Outcomes in PD (SCOPA), anxiety and depression with the Hospital Anxiety and Depression Scale (HADS), and dopaminergic medication requirements (LEDD). Within-group longitudinal outcome changes were tested using Wilcoxon signed-rank and between-group longitudinal differences of change scores with Mann-Whitney U tests. Spearman correlations analyzed the relationships of outcome parameter changes at follow-up.Results:Propensity score matching applied on 159 patients (STN-DBS n = 75, MED n = 84) resulted in 40 patients in each treatment group. At 36-month follow-up, STN-DBS led to significantly better PDSS and PDQ-8 change scores, which were significantly correlated. We observed no significant effects for HADS and no significant correlations between change scores in PDSS, HADS, and LEDD.Conclusions:We report Class IIb evidence of beneficial effects of STN-DBS on quality of sleep at 36-month follow-up, which were associated with QoL improvement independent of depression and dopaminergic medication. Our study highlights the importance of sleep for assessments of DBS outcomes.
LB  - PUB:(DE-HGF)16
C6  - pmid:33074192
UR  - <Go to ISI:>//WOS:000618063800028
DO  - DOI:10.3233/JPD-202278
UR  - https://juser.fz-juelich.de/record/902002
ER  -